Home / Directory / Lysergic Acid Diethylamide (LSD) in Palliative Care
Recruiting trial

Lysergic Acid Diethylamide (LSD) in Palliative Care

Basel, Collonge-Bellerive, Uster, Zurich, Switzerland · Recruiting (ClinicalTrials.gov)

Phase 2 study registered on ClinicalTrials.gov. Condition: Palliative Care, Pain, Anxiety. Interventions listed: Lysergic Acid Diethylamide Tartrate; Lysergic Acid Diethylamide Tartrate. Lead sponsor: University Hospital, Basel, Switzerland. Sites in: Switzerland (4 sites).

Trial listings come from public registries. Taking part is up to the study team, who will check your eligibility. Recruitment status can change at any time, so check the registry record first.

Type
Recruiting trial
Location
Basel, Collonge-Bellerive, Uster, Zurich, Switzerland
Status
Recruiting (ClinicalTrials.gov)
Registry
ClinicalTrials.gov · NCT05883540
Sponsor
University Hospital, Basel, Switzerland
Condition
Palliative Care, Pain, Anxiety
Website
https://clinicaltrials.gov/study/NCT05883540
Source
https://clinicaltrials.gov/study/NCT05883540
Last verified
21 October 2026

About this directory. Psyche Insights lists organisations for information only. A listing is not an endorsement, a recommendation or medical advice, and we do not take referral fees. We list only lawful, regulated services, registered clinical trials and professional training. We do not list retreats or anyone offering psychedelics outside the law. Psilocybin, MDMA, LSD and DMT are controlled drugs in the UK. Eligibility, availability and legal status differ by country and change often. Always check details with the provider or trial team, and talk to your GP or specialist before making any treatment decision. Paid placements are labelled “Featured · Paid placement” and never change our editorial descriptions. See our terms.

Corrections and removal. Spotted an error, or represent a listed organisation and want a listing corrected, updated or removed? Email [email protected] with the page link and the change needed. We aim to reply within 5 working days.

Follow access news each week

New trials, approvals and access routes, UK and Europe first.

Subscribe free →